Both Laughren and Katz are longterm FDA denizens. Each will handle his own set of indications--but I don't see this as a problem, other than Laughren appears to have even less creativity and intelligence than Katz (one of his first suggestions was to greatly extend psychiatric drug trials...to two to three years for chronic conditions like depression (!)) But his Advisory Committee told him this was a bad idea, and he backed off.
News 
Market Data 
Discover 
